No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
229 |
4. Check minimum number of eventsNone |
229 |
5. Include endpointsNone |
229 |
6. Filter based on genotype QC (FinnGen only) |
211 |
Control definitions (FinnGen only)
- Control exclude
- H7_OCUMUSCLE
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Other and unspecified disorders of binocular movement
based on the number of shared cases.
Similar with more cases:
- Other disorders of binocular movement
- Disorders of ocular muscles, binocular movement, accommodation and refraction
- Diseases of the eye and adnexa
- Any prescribed medicine buy
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1678 | 882 | 788 |
| Only index persons | 1432 | 767 | 665 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.03 | 0.02 |
| Only index persons | 0.03 | 0.03 | 0.03 |
| Median age at first event (years) | |||
| Whole population | 25.62 | 31.82 | 18.49 |
| Only index persons | 29.45 | 33.84 | 24.39 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 211 | 136 | 75 |
| Unadjusted period prevalence (%) | 0.04 | 0.05 | 0.03 |
| Median age at first event (years) | 41.42 | 37.69 | 48.18 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 220
- Matched controls
- 2200
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
H51.8
ICD-10 Finland
Other specified disorders of binocular movement
+∞
125.3
108
*
H51.9
ICD-10 Finland
Disorder of binocular movement, unspecified
+∞
92.4
82
*
H53.2
ICD-10 Finland
Diplopia
32.2
62.2
42
16
XCW99
NOMESCO Finland
Other investigative procedure of eye
7.4
31.1
52
88
3788X
ICD-9 Finland
Strabismus and other disorders of binocular eye movements, Other disorders of binocular eye movements
+∞
26.6
25
*
H55
ICD-10 Finland
Nystagmus and other irregular eye movements
146.6
25.2
26
*
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
5.8
23.3
50
107
H50.2
ICD-10 Finland
Vertical strabismus
+∞
21.2
20
*
XA800
NOMESCO Finland
Neuropsychological investigation
6.6
20.0
35
61
H50.1
ICD-10 Finland
Divergent concomitant strabismus
+∞
19.0
18
*
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
4.8
18.7
50
128
H50.0
ICD-10 Finland
Convergent concomitant strabismus
+∞
18.0
17
*
H50.30
ICD-10 Finland
Intermittent esotropy
+∞
16.9
16
*
H50.31
ICD-10 Finland
Intermittent exotropia
+∞
15.8
15
*
Z01.0
ICD-10 Finland
Examination of eyes and vision
3.4
13.6
61
223
H50.52
ICD-10 Finland
Exophoria
74.3
12.7
14
*
H49.2
ICD-10 Finland
Sixth [abducent] nerve palsy
+∞
12.6
12
*
R5110, ,
SPAT
4.6
12.2
31
75
CK2X4
NOMESCO Finland
Optical coherence tomography (OCT) of ocular fundus
4.5
12.1
32
80
R4110
NOMESCO Finland
Physiotherapy
2.8
11.7
86
412
XCK00
NOMESCO Finland
Perimetry
5.9
11.6
22
41
H50.8
ICD-10 Finland
Other specified strabismus
+∞
11.6
11
*
CEC10
NOMESCO Finland
Recession and resection of extraocular muscle
+∞
11.6
11
*
L28
ICPC
Limited function/disability (L)
3.2
11.2
53
198
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
3.8
10.7
36
108
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
3.6
10.7
40
129
TAB00
NOMESCO Finland
Lumbar puncture
4.5
10.0
26
64
Z2445
NOMESCO Finland
Psychologist
4.2
9.9
28
74
CS444
NOMESCO Finland
Visual field testing with Octopus automated perimetry
10.2
9.5
18
19
G35
ICD-10 Finland
Multiple sclerosis
16.5
9.2
14
9
ZXE10
NOMESCO Finland
More than one and less than three hours
2.4
9.1
87
464
ZXE11
NOMESCO Finland
Procedure duration 60 to 89 minutes
3.8
8.8
29
85
A28
ICPC
Limited function/disability NOS
3.0
8.8
44
169
P85
ICPC
Mental retardation
28.8
8.6
11
*
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
7.6
8.5
19
27
CEC00
NOMESCO Finland
Recession of extraocular muscle
+∞
8.4
8
*
WX408
NOMESCO Finland
General anesthesy, balanced
2.5
8.4
71
356
H53.1
ICD-10 Finland
Subjective visual disturbances
3.9
8.3
26
74
ZXE13
NOMESCO Finland
Procedure duration 90 to 119 minutes
4.3
8.1
22
56
303
Kela drug reimbursment
Dimethyl fumarate, interferon beta, glatiramer acetate and teriflunomid (Multiple sclerosis)
23.0
8.1
11
5
Z50.1
ICD-10 Finland
Other physical therapy
4.9
8.0
18
39
Z3229
NOMESCO Finland
Other healthcare associate professional
3.5
8.0
29
91
M03BX01
ATC
baclofen; systemic
10.0
7.9
15
16
AA1AD
NOMESCO Finland
CT of head and brain
2.4
7.9
67
335
N28
ICPC
Limited function/disability (N)
19.2
7.7
11
6
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
14.0
7.5
12
9
G91.1
ICD-10 Finland
Obstructive hydrocephalus
82.8
7.5
8
*
H47.7
ICD-10 Finland
Disorder of visual pathways, unspecified
+∞
7.3
7
*
CEC90
NOMESCO Finland
Total transposition of extraocular muscle or muscles
+∞
7.3
7
*
157
Kela drug reimbursment
Dimethyl fumarate, glatiramer acetate, interferon beta and teriflunomid (Multiple sclerosis)
20.8
7.2
10
5
Z3231
NOMESCO Finland
Registered nurse
2.3
7.2
76
416
F83
ICD-10 Finland
Mixed specific developmental disorders
10.5
7.1
13
13
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
3.4
7.0
27
88
Z2446
NOMESCO Finland
Social worker
3.4
7.0
27
88
Z3226
NOMESCO Finland
Physiotherapist
2.4
7.0
55
264
109
Kela drug reimbursment
Multiple sclerosis
17.4
6.8
10
6
L03AX13
ATC
glatiramer acetate; parenteral
41.4
6.8
8
*
Z87.6
ICD-10 Finland
Personal history of certain conditions arising in the perinatal period
23.3
6.7
9
*
G91.0
ICD-10 Finland
Communicating hydrocephalus
71.8
6.5
7
*
F70.0
ICD-10 Finland
Mild mental retardation, With the statement of no, or minimal, impairment of behaviour
18.7
6.3
9
5
R4120
NOMESCO Finland
Occupational therapy
3.3
6.3
25
83
CEC60
NOMESCO Finland
Transposition of extraocular muscle with adjustable suture
+∞
6.3
6
*
0148, ,
NOMESCO Finland
+∞
6.3
6
*
G80.9
ICD-10 Finland
Cerebral palsy, unspecified
+∞
6.3
6
*
3789X
ICD-9 Finland
Strabismus and other disorders of binocular eye movements, Unspecified disorder of eye movements
+∞
6.3
6
*
H49.1
ICD-10 Finland
Fourth [trochlear] nerve palsy
+∞
6.3
6
*
CA1CG
NOMESCO Finland
Eye and orbita extensive MRI examination with high intensity magnet
27.5
6.3
8
*
ZXD10
NOMESCO Finland
Scheduled procedure
2.1
6.0
87
532
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
27
54
5.56
13.27
2.1
2.4
327.76
32.55
e6/l
0.55
21
40
25
53
5.19
11.50
2.2
2.3
58.32
16.11
e6/l
0.43
19
36
16
16
10.68
8.68
1.0
1.1
—
—
—
0
0
16
17
10.05
8.43
1.0
1.1
—
—
—
0
0
16
17
10.05
8.43
1.0
1.1
—
—
—
0
0
13
9
15.25
8.31
2.6
1.2
—
—
—
0
0
132
867
2.31
8.29
9.1
7.8
1.21
1.21
mmol/l
0.12
120
769
93
541
2.25
7.69
4.0
2.8
0.32
0.37
e6/l
0.17
68
366
121
791
2.18
7.38
8.1
8.0
1.20
1.21
mmol/l
0.56
116
737
60
313
2.26
6.27
3.8
2.9
1.11
2.84
e6/l
1.74
28
151
62
330
2.22
6.16
3.6
2.8
0.67
0.73
e6/l
0.12
30
166
39
172
2.54
5.89
2.0
2.6
88.45
28.32
u/l
0.58
31
141
17
35
5.17
5.88
3.8
4.3
1.90
2.50
ratio
—
8
16
11
12
9.58
5.86
1.0
1.0
—
—
—
0
0
145
1073
2.03
5.75
6.5
5.9
6.31
6.44
mmol/l
0.35
136
1001
152
1161
2.00
5.29
13.7
9.7
3.78
4.02
e9/l
0.79
131
1007
22
76
3.11
5.20
1.4
1.6
32.68
38.95
u/l
0.87
22
69
97
647
1.89
5.01
2.6
3.2
24.24
30.07
u/l
3.32
91
612
38
180
2.34
4.90
9.5
11.3
0.14
0.73
mmol/l
0.42
29
151
9
10
9.32
4.83
1.1
1.7
11.72
11.30
umol/l
—
9
10
18
60
3.18
4.51
1.4
2.3
1.98
3.77
iu/l
—
7
26
8
9
9.17
4.31
1.0
1.1
—
—
—
0
0
101
726
1.72
3.80
2.1
2.0
93.78
93.68
pmol/l
0.01
58
378
41
225
2.01
3.65
1.8
1.5
901.09
1224.79
nmol/l
1.41
32
168
8
13
6.34
3.53
1.1
1.2
1.69
1.80
mmol/l
—
8
13
33
171
2.09
3.42
12.0
12.2
24.48
24.78
mmol/l
0.16
33
171
11
30
3.80
3.13
1.3
1.2
—
—
—
0
0
129
1023
1.63
3.12
5.1
3.5
0.00
0.00
estimate
-0.00
23
209
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
7
13
5.52
2.89
1.0
1.2
—
—
—
0
0
85
618
1.61
2.87
4.5
3.0
2.34
2.35
mmol/l
0.51
79
569
112
872
1.58
2.82
3.1
2.6
78.16
72.97
nmol/l
0.91
104
800
12
39
3.19
2.82
1.2
1.2
1.40
1.36
u/ml
—
5
14
19
88
2.27
2.59
2.4
1.7
—
—
—
0
0
12
42
2.96
2.59
1.2
1.1
3.43
4.06
u/ml
—
7
18
70
496
1.60
2.59
1.6
1.6
21.36
20.80
nmol/l
0.11
63
426
8
21
3.91
2.49
4.4
3.2
1.22
1.19
mmol/l
—
8
21
8
21
3.91
2.49
4.4
3.2
107.88
106.71
mmol/l
—
8
21
64
448
1.60
2.48
2.1
2.3
—
—
—
0
0
124
1007
1.53
2.47
5.2
3.5
0.00
0.00
estimate
-0.00
24
210
116
939
1.50
2.28
6.7
6.8
10.79
11.79
umol/l
0.44
111
891
125
1029
1.50
2.26
5.2
3.6
0.00
0.00
estimate
-0.00
22
195
33
198
1.78
2.25
2.2
1.9
—
—
—
0
0
11
41
2.77
2.24
1.2
1.0
—
—
—
0
0
186
1680
1.69
2.12
28.0
17.5
332.75
333.20
g/l
0.26
186
1674
33
205
1.72
2.00
2.0
1.9
—
—
—
0
0
9
33
2.80
1.95
1.2
1.2
—
—
—
0
0
9
33
2.80
1.95
1.2
1.2
—
—
—
0
0
169
1503
1.54
1.94
5.4
4.5
14.78
14.54
pmol/l
0.72
161
1400
38
248
1.64
1.93
3.1
2.4
22.07
22.94
%
0.13
38
233
27
160
1.78
1.93
4.3
7.3
23.93
23.92
mmol/l
0.00
27
160
201
1868
1.88
1.90
24.0
15.3
139.52
139.63
mmol/l
0.26
196
1827
201
1868
1.88
1.90
23.8
15.3
3.92
3.94
mmol/l
0.36
195
1822
156
1371
1.47
1.84
8.6
7.3
85.71
81.12
u/l
0.32
149
1299
5
12
4.24
1.83
4.0
1.7
—
—
—
0
0
7
23
3.11
1.81
1.3
1.2
—
—
nmol/l
—
0
0
151
1321
1.46
1.80
3.0
3.3
33.63
40.26
u/l
0.58
144
1266
8
31
2.64
1.67
1.0
1.1
—
—
—
0
0
5
14
3.63
1.62
16.6
10.0
953.60
846.71
nmol/l
—
5
14
10
43
2.39
1.61
1.1
1.4
—
—
—
0
0
122
1043
1.38
1.56
3.5
3.2
93.65
86.05
ug/l
0.16
117
996
5
15
3.38
1.53
17.2
19.4
1492.00
1619.13
nmol/l
—
5
15
66
514
1.41
1.46
2.7
2.4
2.73
2.52
mg/l
0.31
61
446
13
67
2.00
1.41
1.2
1.4
—
—
—
0
0
106
898
1.35
1.39
2.8
2.7
—
—
estimate
—
0
0
38
269
1.50
1.38
2.1
2.0
—
—
—
0
0
73
585
1.37
1.36
1.5
1.5
0.46
2.62
u/ml
2.11
21
145
41
297
1.47
1.34
2.9
2.3
12.50
14.09
umol/l
0.81
41
278
5
18
2.82
1.29
2.0
4.2
3.46
2.14
nmol/l
—
5
18
156
1411
1.36
1.27
4.7
4.1
10.69
10.04
mm/h
0.26
150
1321
56
435
1.39
1.25
2.5
2.3
1.18
1.39
mg/l
0.24
46
338
14
78
1.85
1.24
1.6
1.3
—
—
—
0
0
17
101
1.74
1.24
3.3
6.6
0.69
0.63
%
0.67
17
101
20
125
1.66
1.22
2.1
1.6
—
—
—
0
0
5
19
2.67
1.22
1.0
1.2
—
—
—
0
0
17
103
1.70
1.16
3.5
6.5
1.03
1.28
%
0.57
17
103
5
20
2.53
1.15
1.4
1.7
—
—
—
0
0
200
1901
1.57
1.12
22.0
13.3
23.34
21.47
mg/l
0.29
167
1503
9
46
2.00
1.05
1.1
1.4
2.71
3.94
ug/l
—
9
41
190
1793
1.44
1.05
6.4
5.2
1.69
1.86
mu/l
1.53
182
1677
5
22
2.30
1.04
1.0
1.0
—
—
—
0
0
5
22
2.30
1.04
1.0
1.0
—
—
—
0
0
5
22
2.30
1.04
1.0
1.0
—
—
—
0
0
5
22
2.30
1.04
1.0
1.0
—
—
—
0
0
181
1696
1.38
1.02
19.5
12.3
90.37
88.82
ml/min/173m2
0.41
164
1516
22
149
1.53
1.00
1.5
1.4
21.09
22.74
iu/l
0.09
15
117
54
433
1.33
0.98
3.1
3.9
2448.00
1146.15
ng/l
0.65
45
357
14
85
1.69
0.97
1.5
1.7
—
—
—
0
0
204
1962
1.55
0.89
13.4
10.8
23.44
26.03
u/l
1.81
199
1915
41
323
1.33
0.85
1.8
1.7
461.37
24014791.37
pmol/l
0.50
35
279
11
68
1.65
0.73
4.5
5.1
1.26
1.55
%
0.98
11
63
5
25
2.02
0.73
1.0
1.0
—
—
—
0
0
5
26
1.94
0.71
1.0
1.1
—
—
—
0
0
5
28
1.80
0.66
1.6
1.7
—
—
—
0
0
22
165
1.37
0.63
1.6
2.2
13.26
11.73
nmol/l
0.34
22
154
5
30
1.68
0.62
2.4
1.9
11.88
5.75
pmol/l
—
5
30
8
52
1.56
0.60
1.3
1.6
—
—
—
0
0
6
37
1.64
0.56
2.7
1.6
—
—
—
0
0
22
169
1.34
0.56
1.1
1.3
213.80
156.91
u/ml
—
5
67
9
59
1.55
0.55
2.6
1.3
—
—
—
0
0
178
1705
1.23
0.55
4.9
4.4
5.65
5.76
mmol/l
0.73
168
1576
9
62
1.47
0.54
1.0
1.2
—
—
—
0
0
9
63
1.45
0.53
1.0
1.2
—
—
—
0
0
18
135
1.36
0.53
2.7
3.1
71.60
75.40
ml/min/173m2
—
10
55
28
225
1.28
0.53
1.6
3.1
13.90
5.54
umol/l
0.44
22
186
19
144
1.35
0.52
7.4
5.8
1.11
1.16
mmol/l
0.03
13
111
19
146
1.33
0.49
1.1
1.0
—
—
—
0
0
5
33
1.53
0.41
1.0
1.6
—
—
—
0
0
0
17
0.00
0.41
0.0
1.4
—
—
—
0
0
20
160
1.27
0.40
7.2
5.5
4.90
5.09
kpa
0.95
20
155
11
81
1.38
0.37
1.2
1.1
0.83
0.83
g/l
0.02
11
81
29
246
1.21
0.36
3.4
2.7
0.59
0.71
ug/l
0.87
22
152
34
389
0.85
0.34
3.1
2.2
—
—
—
0
0
7
54
1.31
0.30
1.4
1.2
—
—
—
0
0
8
67
1.20
0.26
1.3
1.6
43.29
50.24
ug/l
—
8
67
38
420
0.88
0.24
3.3
2.4
—
—
—
0
0
6
81
0.73
0.24
1.8
1.8
—
—
—
0
0
20
171
1.19
0.24
3.6
3.3
—
—
—
0
0
49
450
1.11
0.23
5.1
3.3
1.02
1.02
kg/l
0.30
31
292
63
587
1.10
0.23
5.5
3.3
14.79
41.55
ng/l
2.05
41
374
40
363
1.12
0.23
3.4
3.7
75.23
301.74
ng/l
1.46
29
247
5
39
1.29
0.23
1.8
2.1
—
—
—
0
0
182
1782
1.12
0.23
4.7
4.5
4.59
4.59
mmol/l
0.01
176
1685
10
79
1.28
0.22
1.2
1.1
1.54
1.54
g/l
—
10
79
10
79
1.28
0.22
1.7
1.3
—
—
—
0
0
5
42
1.19
0.21
1.2
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
3.5
—
4.54
—
0
10
0
10
0.00
0.21
0.0
3.5
—
10.92
—
0
10
15
127
1.19
0.20
1.3
1.4
—
—
—
0
0
7
58
1.21
0.18
1.3
1.3
—
—
—
0
0
61
575
1.08
0.18
1.8
1.9
—
—
—
0
0
8
73
1.10
0.16
1.1
1.7
—
—
—
0
0
171
1679
1.08
0.16
4.1
3.8
1.20
1.24
mmol/l
0.31
158
1564
12
102
1.19
0.15
1.9
1.4
301.13
265.74
miu/ml
—
6
54
17
150
1.14
0.15
7.9
6.4
—
—
—
0
0
18
160
1.14
0.14
2.7
2.2
664.29
8408.56
u/l
—
7
66
61
580
1.07
0.14
5.3
2.9
0.05
0.00
estimate
0.48
22
173
149
1459
1.07
0.14
4.0
3.8
—
—
—
0
0
78
749
1.06
0.14
5.9
3.3
0.00
0.01
estimate
0.50
20
173
34
317
1.09
0.13
4.4
4.3
19.41
22.37
%
0.78
15
148
53
507
1.06
0.10
3.2
4.0
14.74
10.73
mg/mmol
0.17
33
329
5
44
1.14
0.10
1.4
1.5
—
—
—
0
0
37
351
1.07
0.09
1.2
1.3
0.97
8.93
u/ml
3.54
12
140
5
63
0.79
0.08
1.8
2.0
—
—
—
0
0
5
64
0.78
0.08
2.4
3.2
24.62
24.64
mmol/l
—
5
64
179
1776
1.04
0.05
4.7
4.4
1.46
1.46
mmol/l
0.05
171
1667
10
91
1.10
0.04
1.7
1.8
—
—
—
0
0
11
101
1.09
0.04
1.8
1.5
0.99
1.24
ratio
—
6
60
11
101
1.09
0.04
1.9
1.5
0.86
0.94
ratio
—
5
60
11
101
1.09
0.04
1.8
1.5
1.21
1.17
ratio
—
5
60
21
220
0.95
0.03
3.0
2.0
—
—
—
0
0
25
259
0.96
0.02
3.1
2.2
—
—
—
0
0
163
1640
0.98
0.02
6.1
5.4
37.55
38.29
mmol/mol
0.54
156
1560
80
791
1.02
0.02
1.9
1.9
1.51
1.32
mmol/l
0.96
74
690
13
137
0.95
0.01
1.6
1.4
—
—
—
0
0
180
1794
1.02
0.00
5.3
5.0
2.76
2.69
mmol/l
0.53
172
1691
53
536
0.99
0.00
5.9
3.4
0.00
0.00
estimate
0.50
20
200
10
98
1.02
0.00
1.9
1.5
—
—
—
0
0
15
149
1.01
0.00
6.5
2.3
0.14
0.14
e6/l
0.01
15
139
38
376
1.01
0.00
1.4
1.5
—
—
—
0
0
12
125
0.96
0.00
1.5
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
5.6
—
6.13
—
0
7
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
5.8
—
1.23
—
0
6
38
380
1.00
-0.00
1.5
1.3
24.96
31.12
iu/ml
—
10
104
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.6
—
42.02
—
0
5
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
9.11
—
0
5
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
5
59
0.84
-0.00
1.8
1.9
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
72.00
—
0
7
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
3.2
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint H7_BINOCUMOVNAS and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| H7_BINOCUMOVNAS | 1.577 [1.15, 2.17] | 0.005 |
| Birth year | 0.991 [0.98, 1.0] | 0.051 |
During the follow-up period (1.1.1998 — 31.12.2019), 66 out of 658 females with H7_BINOCUMOVNAS died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| H7_BINOCUMOVNAS | 2.058 [1.46, 2.9] | < 0.001 |
| Birth year | 0.989 [0.98, 1.0] | 0.023 |
During the follow-up period (1.1.1998 — 31.12.2019), 70 out of 582 males with H7_BINOCUMOVNAS died.
Mortality risk
Mortality risk for people of age
years, who have H7_BINOCUMOVNAS.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.113% | 0.431% |
| 5 | 0.795% | 2.599% |
| 10 | 1.949% | 6.692% |
| 15 | 3.791% | 11.912% |
| 20 | 6.634% | 18.919% |
Relationships between endpoints
↥Index endpoint: H7_BINOCUMOVNAS – Other and unspecified disorders of binocular movement
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data